ScinoPharm Taiwan, Ltd.

Ticker: TWSE 1789

Third Quarter 2016 Online Investor Meeting

November 9, 2016

Disclaimer

This material has been prepared by ScinoPharm Taiwan, Ltd. ("ScinoPharm").

Any opinions expressed in this material are subject to change without notice as a result of using different assumptions. ScinoPharm is under no obligation to update or keep current the information contained herein.

The **information contained** in this presentation **is** ScinoPharm's **confidential** information. Any disclosure, copying, distribution or any action taken or omitted to be taken in reliance on it is prohibited and may be unlawful.

No representation or warranty, express or implied, is or **will be made** in or in relation to, and no responsibility or liability is or will be accepted by the Company **as to**, the **accuracy or completeness** of this material and any liability therefore is hereby expressly disclaimed.

Statements made in this presentation include forward-looking statements, which include, without limitation, statements about the issues, plans and expectations of ScinoPharm. Without limiting the foregoing, statements including the words "believes", "anticipates", "plans", "expects" and similar expressions are also forward-looking statements. Forward-looking statements reflect, among other things, management's plans and objectives for future operations, current views with respect to future events and future economic performances and projections of various financial items. **These forward-looking statements involve known and unknown risks**, uncertainties and other factors **which may cause actual results to differ materially from those implied** by such forward-looking statements.

ScinoPharm
TWSE 1789

Table of Content

- Overview of ScinoPharm
- Financial & Operating Results in Q3, 2016
- Business Updates

Overview of ScinoPharm

Business Overview

- Company specializes in high potency (steroid/cytotoxic) APIs and is expanding into sterile/aseptic injectable formulations
- Facility & organization built in Taiwan and expanding in China with a new GMP plant in Changshu & marketing base in Shanghai
- 71 generic APIs in current portfolio with 25 APIs launched; 52 US DMFs filed (743 DMFs WW), 31 US DMFs in oncology APIs. 100+ NCE CRAM projects, with 5 APIs launched and 5 in phase III for NDA filing in 1-3 years
- Fully compliant with world-class cGMPs and international regulatory requirements; Certified by US FDA, EMA, EDQM, Australian TGA, Japanese PMDA, etc.

World Class API Facilities

Taiwan

- 6.6 hectares of land, 330K sqft facilities with >200M^3 reactor volume
- 5 of 16 production lines equipped with high potency capabilities for cytotoxic/steroids
- Passed US FDA, EMA, EDQM, Australian TGA, Japanese PMDA inspections & 300+ cGMP customer audits
- Provides comprehensive contract research & manufacturing services for Brand drug companies
- Global market served

China

- 6.5 hectares of land with > 250M^3 reactor volume
- 3 of 7 production lines equipped with high potency capabilities for cytotoxics
- US FDA approved cGMP facility for intermediates & high potency APIs
- Full scope capabilities in developing and producing APIs from small to large scale for generic & CRAM markets
- Global market served including China

Strong Generics Product Portfolio



Note: Other (Women's Health, Gastrointestinal, Immunology and Metabolic)

ScinoPharm
TWSE 1789

ScinoPharm - Oncology API Leader





Source: US FDA DMF Q1 2016 database

ScinoPharm
TWSE 1789

We are Transforming our Company



ScinoPharm
TWSE 1789

Keys to Generic Formulation Business

Opportunity

- ✓ Already the leader in providing oncology APIs to regulated markets worldwide
- ✓ Injectable CMOs are in short supply
- ✓ Can be customer's injectables provider by developing formulations using our own oncology APIs or others' APIs, up to and including filing for ANDA with FDA

Strategy

- ✓ Developing dossiers per our difficult-to-make APIs to increase value proposition in the supply chain
- ✓ Targeted delivery & extended release of proven APIs via 505(b)(2) fast track
- ✓ Collaborating with start-ups & research institutes, focusing on un-met oncology medical needs of high prevalence in Asia

Tactics

- ✓ Expanding formulation portfolio
- ✓ Establishing on-site oncology injectable facility and providing an integrated supply chain
- ✓ Promoting our formulations via strategic alliances, especially in China and US/EU

Results

- **2 US ANDAs**
- **11 co-developing and cost/profit sharing products with various partners**

Strategic Alliance Highlights

* Already launched

Partner	Product	Indications	Region	Launch Year(E)	Remarks
Genovate	Entecavir	Hepatitis B Viral	Taiwan	2013*	1st co-developed formulation product launch
Sagent	Oncology Injectable	Myeloid Leukemia	US	2017	1st US ANDA filing, triggered US FDA inspection in Changshu site
Foresee	Leuprolide	Prostate cancer	US	2018	505(b)2 NDA CRAM + Equity
Coland	Bortezomib	Multiple Myeloma	China	2020	1st co-developed drug in China to trigger CFDA inspection in Changshu site
	Azacitidine	MDS	China	2021	Co-developed formulation in China
Lee's Pharma	Fondaparinux	Anti-thrombotic	China	2021	Co-development collaboration
	Travoprost Bimatoprost	Glaucoma	China	2020	
Nanjing King Friend	Regadenoson	Stress agent for heart scan	China	2020	Co-developed formulation in China
US partner	Project A	non-small cell lung cancer	US	2018	US NDA 505(b)2 with Paragraph IV filing / The estimated launch year is subject to litigation results
US & China partners	Project B	imaging agent	US	2020	ANDA with Paragraph IV filing / The estimated launch year is subject to litigation results

Progress of Injectable Business

Product	Oncology Injectable	Fondaparinux	Others (10 drugs)
Partner	Co-development with Sagent	US-self development+local marketer CN-collaboration with Lee's Pharma	Self development and partnership
Formulation Production	Kindos Pharmaceuticals, China	CMO	CMO + In-house production
Type	Generic	Generic	New Drug Generic
Indications	Myeloid Leukemia	Anti-thrombotic	Cancer, diabetes, osteoporosis, multiple sclerosis and antinauseant
Market Size	US: US$200M	US:US$100M CN:US$80M	
Launch Year(E)	2017	US:2017 CN:2020	After 2019

Financial & Operating Results in Q3, 2016

Quarterly P&L - Consolidated

In NT$ million, except for EPS	3Q,'16 (Reviewed)	2Q,'16 (Reviewed)	3Q,'15 (Reviewed)	QoQ	YoY
Operating Revenue	992	1,015	983	*-2%*	*1%*
Gross Profit	466	465	453		
Gross margin	*47%*	*46%*	*46%*		
Operating Expenses	(233)	(236)	(234)		
Operating Income	233	229	219	*2%*	*7%*
Operating margin	*24%*	*23%*	*22%*		
Other Rev.(Exp.)	(26)	(29)	(15)		
Net Income before Tax	207	200	204	*3%*	*1%*
Net Income after Tax	166	174	195	*-5%*	*-15%*
Net margin after tax	*17%*	*17%*	*20%*		
EPS (after tax)	0.22	0.23	0.26		

Cumulative P&L - Consolidated

In NT$ million, except for EPS	1Q~3Q,'16 (Reviewed)	1Q~3Q,'15 (Reviewed)	YoY
Net Sales	3,028	2,925	*4%*
Gross Profit	1,362	1,162	
Gross margin	*45%*	*39%*	
Operating Expenses	(704)	(676)	
Operating Income	658	486	*35%*
Operating margin	*22%*	*16%*	
Other Rev.(Exp.)	(60)	85	
Net Income before Tax	598	571	*5%*
Net Income after Tax	512	440	*16%*
Net margin after tax	*17%*	*15%*	
EPS (after tax)	0.67	0.58	*16%*

Balance Sheet- Consolidated

In NT$ million	2016/09/30 (Reviewed)		2015/09/30 (Reviewed)	
Cash and Cash Equivalents	3,137	*25%*	1,846	*15%*
Accounts Receivable	614	*5%*	648	*5%*
Inventories	2,018	*16%*	2,289	*19%*
Long-Term Investments	364	*3%*	339	*3%*
Property, plant and equipment	5,248	*42%*	5,143	*43%*
Other Current/Non-Current Assets	1,128	*9%*	1,730	*15%*
Total Assets	12,509	*100%*	11,995	*100%*
Current Liabilities	1,534	*12%*	2,199	*18%*
L-T Liabilities and Others	880	*7%*	95	*1%*
Stockholders' Equities	10,095	*81%*	9,701	*81%*

Cash Flows- Consolidated

In NT$ million	1Q~3Q 2016 (Reviewed)	1Q~3Q 2015 (Reviewed)
Cash and cash equivalents at beginning of period	2,336	1,928
Cash flows from operating activities	1,130	764
CAPEX	(420)	(582)
Short-term borrowings	(747)	402
Long-term borrowings	812	-
Cash Dividends	(219)	(141)
Others	245	(525)
Cash and cash equivalents at end of period	3,137	1,846

Sales by Business

2015 Q1-Q3



2016 Q1-Q3



ScinoPharm
TWSE 1789

Sales by Indication



ScinoPharm
TWSE 1789

Sales by Region

2016 Q1-Q3



2015 Q1-Q3



ScinoPharm
TWSE 1789

Business Updates

Passed EDQM Inspection Successfully

- Successfully completed a GMP inspection by European Directorate for the Quality of Medicine & (EDQM) for the 1st time
- Inspection of sites is a fundamental part of the EDQM's oversight of APIs via the Certificate of Suitability (CEP) system, and is used to determine whether substances are being produced in accordance with the submitted product dossier and Good Manufacturing Practices
- A 3-day onsite inspection to evaluate quality system, facilities, storage, manufacturing, packaging, and labs for 2 APIs with CEP approved from this inspection

2016 CPhI WW Trend Observations

- **Big pharmas focus on core business via downsizing and outsourcing**
  → **Accelerate our new generic API and CRAM business model**

- **High-end APIs outsourced to India/China have gradually returned to US/EU due to GMP compliance risks and rise in cost**
  → **ScinoPharm's proven track record of high quality timely captures the high-end API business**

- **High demand for oncology sterile injectable drugs**
  → **Vertical integration including formulation by developing our own injectable drugs and building our oncology injectable plant**

- **M&A activity within the global generic industry leading to hybrid generic-branded models**
  → **ScinoPharm exploring new business models according to customers' M&A activities**

Diversified CRAM Portfolio

Stage	First Launch Year	Indication	Location
Commercial	2005	Eluting Stent	US
Commercial	2009/2013	Skin Infection/HAP	US/EU
Commercial	2011	Depression	US
Commercial	2012	Obesity	US
Commercial	2013	Seizure	US
Stage	**Est. NDA Filing Year**	**Indication**	**Location**
Phase III	2016*	Infections	US / EU / Asia
Phase III	2017	Ovarian Cancer	US / EU
Phase III	2017	Prostate Cancer	US
Phase III	2017	Ovarian Cancer	CN
Phase III	2018	Parkinson's Disease	US

* Filed

Selected List of CRAM Projects at Changshu

Customer	Project Type	Product Indication/stage	Product Type	Remarks/ Market
Top 10 global pharma	CMO	Approved antidepressant drug in US	GMP Intermediate	Passed Mexican authority (APIF) GMP inspection
Top 5 global pharma	CMO	Approved African sleeping disease drug	API	Site transfer from Taiwan
Lee's Pharma	CRO / CMO	>15 projects, including topical anesthetic, brain tumor, antibiotic, hypertension, eye drops, etc.	API	China
China pharm company	CRO	Phase II/ III clinical trial for cancer	API	China
China pharm company	CRO	Phase IIb for age-related macular degeneration	API	US/China
Taigen Biotech	CRO	Phase II clinical trial for myocardial infarction	API	China/Taiwan
US-based new drug company	CRO	Phase II clinical trial for prevention of HIV infection	API	US
Alsan Pharmaceuticals	CRO	Phase II clinical trial for cancer	API	China/Global
Top 5 global pharma	CRO	Phase II clinical trial for diabetes	Intermediate	US
Top 5 global pharma	CRO	Phase I clinical trial	API	NA
US NASDAQ listed pharma	CRO	Phase III clinical trial for opioid-induced constipation	Crude API	US

2016 API Product Launch Plan

	API	Region	Indication	Brand Marketer	Regional Sales	WW Sales
✔	Azacitidine	USA	Myelodysplastic syndrome (MDS)	Celgene	US$248.1M	US$751.6M
	Desmopressin Acetate	USA	Polyuria	Ferring	US$150.1M	US$395.8M
✔	Entecavir	USA Singapore Australia	Hepatitis B Virus (HBV)	Bristol-Myers	US$262.5M (USA only)	US$1,576.6M
✔	Flumazenil	Korea	Reversal of the sedative effects of benzodiazepines	Roche	N/A	US$84.0M
✔	Gemcitabine HCl	Middle East	Pancreas, Lung, Ovary, and Breast Cancers.	Eli Lilly	N/A	US$547.9M
	Tamsulosin HCl	USA	Benign Prostatic Hyperplasia (BPH)	Boehringer Ingelheim	US$410.0M	US$1,818.4M

Source: IMS Data (2014Q4-2015Q3)

✔ Launched

Pipeline Outlook



ScinoPharm
TWSE 1789

Questions

&

Answers

Brand Quality with Asian Advantages

www.scinopharm.com

ScinoPharm
TWSE 1789